Call
+918447748545

Published on: Jul 17, 2020
2 minute read
By: Dr Rajan Choudhary

MRNA Vaccine Against SARS CoV2

An mRNA Vaccine against SARS CoV2

We have previously discussed vaccines against SARS-CoV-2, the virus responsible for COVID-19. On the 14th of July, a preliminary study was published in the New England Journal of Medicine, an internationally reputable medical journal. This study looks at mRNA vaccines in Phase 1 human clinical trials, a first for the virus. Here we will discuss what this means and the results of the study.

mRNA vaccine

Vaccines target the immune system’s memory by presenting them with pieces of these infective diseases. The small amounts do not cause any infective symptoms, but if the person is infected later in life their body will mount a quicker response and prevent them from falling ill. These vaccines can contain broken up parts of the organisms, “dead” organisms or “live” versions that have been severely weakened so they cannot cause any harm.

In 2018 a new type of vaccine was described. Instead of using pre-made protein markers that identify infectious organisms, mRNA vaccines contain genetic material with instructions to produce these markers. Once injected, the person’s cells use these instructions to produce copies of these protein markers. These markers are displayed on the surface of the cell, which in turn is recognized by the immune system, initiating an immune response and producing protective antibodies.

BENEFITS

A major advantage of RNA vaccines is the ease by which they can be made in a laboratory from a DNA template. During a pandemic, this would result in a rapid response and vaccine against a new disease. Conventional vaccines require the use of chicken eggs or cells to produce the vaccines, which can be expensive and time-consuming. These vaccines can be delivered via injections into the skin, blood, muscle, or organs, needle-free into the skin, or via nasal spray. Because these vaccines are so new, we still do not know the best way to deliver it.

Because these vaccines are not made with parts of infective organisms or from live organisms, they are not infectious and will not cause harm through a strong immune response to the vaccine itself, or by causing the disease they aim to vaccinate against. They also appear to be very efficient at generating a reliable immune response to produce antibodies and are well tolerated with few side effects.

NEEDS IMPROVEMENT

Because these types of vaccines are so new there is still a lot we do not understand about them. They may cause unintended effects that we have not yet encountered in human clinical studies. These vaccines also need to be frozen or refrigerated, and so would not be suitable for countries with limited or no refrigeration facilities.

COVID

The SARS-CoV-2 mRNA vaccine codes for one of the virus’ surface spike proteins, responsible for recognizing target cells and fusing the virus into the cell for entry and infection. It was previously recognized as a target for the SARS and MERS viruses.

45 participants received 2 intramuscular injections 28 days apart. None of the participants had any serious side effects after the first injection, or any side effects significant enough to stop the trial. Many had minor to moderate side effects after their second injection (such as fatigue, chills, headache, myalgia, and pain at the injection site), and half the participants taking high dose vaccines had febrile side effects. Overall the side effects were rated as acceptable.

Prior to the vaccine trials, none of the participants had any antibodies against COVID, or any capacity to stop a COIVD infection. After the injections, all participants had noticeable increases in antibodies produced, measurable in their blood. After 43 days, the participant's blood had enough antibodies to reduce infection by SARS-CoV-2 by over 80%.

What is the takeaway? The vaccine is capable of producing an adequate response to protect the vaccine recipient without eliciting any major side effects. These results will be used in phase 2 clinical trials (enrolment began in May) and a phase 3 trial in July 2020. Essentially this means further human trials to further look for side effects in a larger number of volunteers with a more diverse health profile.

This represents an interesting development in producing a rapid vaccine against a new virus responsible for a world-changing pandemic. This new type of vaccine may be the future of vaccines for a broader range of viruses, bacteria, and even cancers.

Read Blog

Difference Between Sadness and Depression: Understanding Normal Emotions vs Mental Illness

Feeling low or unhappy is a part of being human. However, not all low moods are the same. Many people confuse sadness with depression, which can delay proper support and treatment. Understanding the difference between sadness and depression is crucial for mental health awareness, early intervention and reducing stigma.

In India, mental health conditions are often misunderstood, with emotional distress frequently dismissed as temporary sadness.

What Is Sadness?

Sadness is a normal human emotion.

It usually occurs due to:

loss or disappointment
relationship issues
failure or stress
temporary life challenges

Sadness serves a psychological purpose, allowing individuals to process emotions and adapt.

Key Characteristics of Sadness

Sadness is:

situational
temporary
emotionally painful but manageable
responsive to support and positive events

A person experiencing sadness can still function, enjoy moments and feel hopeful.

What Is Depression?

Depression is a medical condition classified as a mood disorder.

It affects:

emotions
thinking patterns
behaviour
physical health

According to WHO, depression is one of the leading causes of disability worldwide.

Core Symptoms of Depression

Depression involves a combination of symptoms such as:

persistent low mood
loss of interest or pleasure
fatigue
sleep disturbances
appetite changes
feelings of worthlessness
difficulty concentrating

These symptoms last at least two weeks or longer.

Duration: A Key Difference

One major difference lies in duration.

Sadness:

lasts hours or days
improves with time

Depression:

lasts weeks or months
persists despite positive events

Duration helps distinguish emotional response from illness.

Impact on Daily Functioning

Sadness:

allows continuation of work and relationships
may reduce motivation temporarily

Depression:

interferes with work, studies and relationships
reduces self-care and productivity

Functional impairment is a defining feature of depression.

Emotional Experience: Sadness vs Depression

Sadness:

allows emotional range
moments of joy still occur

Depression:

creates emotional numbness
joy and interest disappear

People with depression often describe feeling empty rather than sad.

Physical Symptoms in Depression

Depression is not only emotional.

Physical symptoms include:

chronic fatigue
body aches
headaches
digestive issues

ICMR mental health studies highlight the physical burden of depression.

Thought Patterns and Self-Perception

Sadness:

thoughts remain realistic
self-worth is preserved

Depression:

negative self-talk dominates
feelings of guilt and worthlessness increase

These cognitive changes deepen emotional suffering.

Risk Factors for Depression

Factors increasing depression risk include:

chronic stress
trauma
family history
medical illnesses
hormonal changes

NFHS-5 data indicates rising mental health concerns among young adults.

Can Sadness Turn Into Depression?

Yes, prolonged or unresolved sadness can progress into depression.

This is more likely when:

stressors are ongoing
support systems are weak
coping mechanisms are limited

Early emotional support can prevent progression.

When to Seek Professional Help

Seek help if:

low mood lasts more than two weeks
daily functioning is affected
sleep and appetite are disturbed
thoughts of self-harm occur

Early care leads to better outcomes.

Treatment Differences

Sadness:

improves with rest, support and time

Depression:

requires psychotherapy
may need medication
benefits from structured care

WHO emphasises early treatment to reduce disability.

Role of Social Support

Support systems help both conditions but are essential for recovery.

Depression recovery improves with:

understanding family
supportive workplaces
accessible mental healthcare

Stigma reduction is key.

Mental Health Awareness in India

Mental health remains underdiagnosed in India.

NITI Aayog reports:

limited access to mental health services
low awareness
high stigma

Education helps bridge this gap.

Importance of Early Recognition

Recognising depression early:

prevents worsening
reduces suicide risk
improves quality of life

Delay increases suffering and complications.

Supporting Someone With Depression

Helpful actions include:

listening without judgement
encouraging professional help
avoiding minimising feelings

Compassion is more effective than advice.

Conclusion

Understanding the difference between sadness and depression is essential for emotional wellbeing and mental health care. Sadness is a natural, temporary response to life events, while depression is a serious medical condition that affects thoughts, emotions and daily functioning. Recognising the signs early and seeking appropriate help can prevent long-term suffering and promote recovery. Mental health deserves the same attention and care as physical health.

References

World Health Organization (WHO) – Depression and Mental Health Disorders
Indian Council of Medical Research (ICMR) – Mental Health Research and Burden
National Family Health Survey (NFHS-5) – Mental Health Indicators
Lancet – Depression, Disability and Public Health
NITI Aayog – National Mental Health Policy and Awareness Reports
Statista – Global and Indian Mental Health Trends

Request A Callback

+91

By using this website/app, I confirm that I am at least 18 years old and consent to the processing of my personal data in accordance with the Terms of Service, Privacy Policy, and Declaration.